Compare ADMA Biologics Inc (ADMA) vs Dollar General Corp. (DG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Dollar General Corp. — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Dollar General Corp. trades at $116.04 (market cap $25.46B). The key difference: Dollar General Corp. is far larger — about 12× ADMA Biologics Inc's market cap, and Dollar General Corp. pays a 2.04% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | DG | |
|---|---|---|
Market Cap | $2.13B | $25.46B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $156.26 |
52-Week Low | $7.60 | $95.94 |
Enterprise Value | $2.20B | $39.91B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Dollar General (DG) trades at $115.43, down 2.32% on the day, with technical indicators showing a neutral to bearish short-term bias. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.00 surpassing the $1.89 estimate. Fundamentals reveal steady revenue growth to $40.61 billion in 2025, though net income margin has compressed to 2.77%. Positive cash flow trends and a manageable debt-to-asset ratio of 20.03% support financial health.
The investment outlook is cautiously optimistic, driven by analyst consensus favoring a Buy rating with a $128.91 price target, implying ~12% upside. Key opportunities include margin expansion initiatives and the DG Media Network, while risks involve consumer spending sensitivity and competitive pressures. The current valuation at a P/E of 16.45 appears reasonable relative to historical performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →
